摘要
目的评价利奈唑胺治疗耐药结核病的临床疗效及安全性。方法将我院收治的42例耐药结核病患者随机分为观察组25例和对照组17例,对照组给予常规化疗,观察组在对照组基础上加用利奈唑胺;对比两组患者临床疗效,并分析不良反应发生情况。结果观察组患者临床病症改善情况、影像学改变情况以及痰菌变化情况均优于对照组,两组比较差异有统计学意义(P<0.05);观察组不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论利奈唑胺治疗耐药结核病临床疗效显著,不良反应可控,可以用于耐药结核病的治疗。
Objective To evaluate the clinical efficacy and safety of linezolid in the treatment of drug resistant tuberculosis （ TB ）. Methods 42 cases of TB patients in our hospital were randomly divided into observation group （n = 25 ） and control group （n = 17 ） , control group was given conventional chemotherapy, observation group was add- ed with linezolid on the basis of control group. The clinical curative effect of the two groups was compared, and the oc- currence of adverse reactions was analyzed. Results The improvement of clinical symptom, the imaging changes and sputum of observation group were superior to those of control group, there was significant difference between the two groups （ P 〈 0. 05 ） ; the incidence of adverse reactions had no significant difference between the two groups （ P 〉 0. 05 ）. Conclusion Clinical efficacy of linezolid in the treatment of drug-resistant TB is significant, has low adverse reactions, and can be used for the treatment of drug resistant tuberculosis.
出处
《实用药物与临床》
CAS
2014年第3期375-377,共3页
Practical Pharmacy and Clinical Remedies
